Aliqopa (Copanlisib)
- Medicine Name: Aliqopa
- Generic Name: Copanlisib
- Dosage Form & Strength: For injection: 60 mg as a lyophilized solid in single-dose vial
- Manufactured By: Bayer Corporation
Medical Uses
Aliqopa is a kinase inhibitor used to treat adult patients with relapsed follicular lymphoma (FL) who have previously received at least a couple of systemic treatments.
Recommended Dosage: The recommended dose of Aliqopa injection is 60 mg administered as a 60 minutes intravenous infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3-weeks on and 1-week off). Continue treatment with Aliqopa until the disease is progressive or unacceptable toxicity occurs.
Warning & Precautions
- Severe, including fatal, infections occurred in patients treated with Copanlisib monotherapy. Monitor patients for signs/symptoms of infection and withhold Copanlisib 60mg injection for Grade 3 and higher infection.
- Severe pneumocystis jiroveci pneumonia (PJP) may emerge in patients taken treatment with Aliqopa monotherapy. Prior to initiating therapy, consider PJP prophylaxis for individuals at risk.
- Grade 3/4 hyperglycemia (blood glucose 250 mg/dL or higher) and severe hyperglycemic events may occur in patients treated with Aliqopa monotherapy. Achieve optimal blood glucose control prior to starting each infusion. Withhold, reduce dose, or discontinue therapy depending on the severity and persistence of hyperglycemia.
- Grade 3 hypertension (systolic 160 mmHg or higher or diastolic 100 mmHg or higher) occurred in patients treated with Aliqopa monotherapy. Monitor BP pre- and post-infusion. Withhold, reduce dose, or interrupt aliqopa 60 mg injection depending on the severity and persistence of hypertension.
- Non-infectious pneumonitis emerged in patients treated with Copanlisib monotherapy. Withhold this drug and conduct a diagnostic evaluation of a patient who is experiencing pulmonary symptoms such as dyspnea, cough, hypoxia, or interstitial infiltrates on radiologic exam.
- Grade 3/4 neutropenia may occur in patients treated with injection aliqopa 60 mg. Severe neutropenic events may occur. Monitor blood counts at least on a weekly basis during therapy. Withhold, reduce dose, or interrupt inj aliqopa 60 mg on behalf of severity and persistence of neutropenia.
- Based on outcomes in animals and its mechanism of action, this medication can cause fetal harm if received by a pregnant woman. Respective women of reproductive age and men with women partners of reproductive age should use apt contraception during therapy and for at least 30 days after the final dose.
Documentation & Availability
What documents are required to import ALIQOPA to India?
ALIQOPA (copanlisib) injections can be imported by patients or government hospitals on the name of the patients only.
The following documentation is required to import the product:
- A valid prescription from a qualified doctor.
- Patient’s diagnostic reports.
- Patient’s ID proof (issued by the Government of India).
How is the order confirmed?
The order will be confirmed only after the receipt of:
- A valid prescription from a doctor.
- Import permit if applicable.
Is ALIQOPA available in India?
ALIQOPA (copanlisib injection) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
ALIQOPA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of ALIQOPA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for Aliqopa injection price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
Indian Pharma Network is able to source the ALIQOPA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Aliqopa®?
Copanlisib is Generic Name for the trade name drug Aliqopa®.
What is the Manufacturer Name of Aliqopa®?
Aliqopa® is manufactured by Bayer HealthCare Pharmaceuticals Inc.
Is Aliqopa® approved by the FDA?
Yes, Aliqopa® is approved by the FDA. Date of approval: September 14, 2017.
What is the dosage and form of Aliqopa® supplied?
Aliqopa® is supplied for injection: 60 mg as a lyophilized solid in single-dose vial for reconstitution for intravenous administration.
What are the most common side effects due to Aliqopa®?
Most common side effects due to Aliqopa® include: lower respiratory tract infections, hyperglycemia, hypertension, diarrhea, decreased general strength and energy, nausea, leukopenia, neutropenia, thrombocytopenia.
Can I take Aliqopa if I’m pregnant or breastfeeding?
You must have a negative pregnancy test prior to start taking Aliqopa. Avoid breastfeeding while using this medication, and for at least 30 days after the final dose.
How much does Aliqopa® cost in India?
The aliqopa cost in India is reasonable and can vary. In order to procure this follicular lymphoma medication authentically, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Aliqopa®?
Vials of Aliqopa must be refrigerated at temperature 2°C to 8°C (36°F to 46°F).
What are the Highlights of prescribing information for Aliqopa®?
Click Here to download full Aliqopa prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Email Address
Sshealthcare1012@gmail.com
+91 7575883015
Landline
079 48916267
Disclaimer
All Trademarks and Brands that appear on the website belong to their respective owners, and S S Healthcare does not lay any claim on them. We only provide information.
